According to Forbes, the 55-year-old plaintiff asked ChatGPT about chest pain and other symptoms. The chatbot provided reassurance that his condition was unlikely to be serious, leading him to postpone seeking emergency care. He was later diagnosed with a blood clot in his lungs—a life-threatening condition that required immediate hospitalization.
This case exposes a core tension in how AI companies market their products. They've spent years positioning chatbots as helpful, conversational companions while burying liability disclaimers in terms of service. Now courts will decide whether a product that sounds authoritative and personal can hide behind boilerplate warnings. The outcome will shape how AI firms design and communicate medical guidance going forward.
OpenAI will likely argue that ChatGPT includes explicit warnings against using it for medical diagnosis, and that users bear responsibility for seeking professional care. The company may contend that no reasonable person should treat a chatbot as a substitute for a doctor, and that the plaintiff's reliance was his own choice.
OpenAI's real problem isn't the disclaimer. When a chatbot speaks in calm, situational language and offers personalized responses, users treat it like advice, not a search result. Courts see through that gap. If ChatGPT's interface and tone create the impression of medical guidance, a judge will weigh that against the fine print. OpenAI wanted the trust of a helpful assistant without the accountability of one. That trade-off is collapsing.
Filed to the Media desk · Jul 24